HOPE Therapeutics, a wholly‑owned subsidiary of NRx Pharmaceuticals, has started patient care using the Ampa ONE‑D protocol in Florida. The single‑day treatment combines transcranial magnetic stimulation with physician‑prescribed D‑cycloserine and lisdexamfetamine. The protocol was first deployed in Sarasota, Naples, and Fort Myers, with plans to add three additional sites by year‑end 2025.
Clinical data from nonrandomized trials show an 87 % response rate and a 72 % remission rate. The Ampa device has received FDA clearance, but neither D‑cycloserine nor lisdexamfetamine is FDA‑approved for the depression indication used in the protocol. The combination is also a key component of NRx’s NRX‑101 candidate, which has Breakthrough Therapy designation for suicidal bipolar depression.
The launch is part of HOPE’s strategy to build a national network of interventional psychiatry clinics that offer ketamine, TMS, and other neuroplastic therapies. Management expects the initial three acquired clinics to generate $15 million or more in annual revenue on a forward‑looking basis, and the expansion to six sites is projected to increase revenue and EBITDA potential.
NRx Pharmaceuticals, the parent company, reported a net loss of $6.53 million for Q2 2025 and $5.5 million for Q1 2025, a modest improvement from the $6.5 million loss in Q1 2024. The company’s focus on operational efficiencies and securing funding supports the rollout of HOPE’s services as a near‑term revenue driver while the drug pipeline continues to develop.
The Ampa ONE‑D protocol offers a differentiated, efficient alternative to traditional multi‑session TMS programs, potentially expanding access to depression treatment and creating new revenue streams for HOPE and NRx. The combination of clinical efficacy, FDA‑cleared device, and strategic expansion positions the company to capitalize on the growing demand for rapid‑acting depression therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.